Report Wire

News at Another Perspective

Coronavirus India LIVE updates: ‘Centre will soon say there was no Covid,’ says Delhi Health Minister

2 min read

Bengaluru: Passengers put on face masks for prevention in opposition to COVID-19, at Sangolli Rayanna railway station in Bengaluru, Thursday, July 15, 2021. (PTI Photo/Shailendra Bhojak)
Prime Minister Narendra Modi on Tuesday apprised the ground leaders of each Houses on Covid-19 state of affairs and mentioned that “pandemic should not be a matter of politics and is a matter of concern for entire humanity,” an announcement from the Ministry of Parliamentary Affairs acknowledged. PM additionally pressured the necessity to correctly plan the vaccination drives on the district degree primarily based on the advance availability info.
Earlier within the day, the ICMR mentioned that it might be clever to think about reopening main faculties first as kids can deal with viral an infection a lot better. In the newest nationwide sero survey carried out by ICMR in June-July, one third of the inhabitants didn’t have SARS-CoV-2 antibodies which means that about 40 crore individuals nonetheless susceptible to Covid-19 an infection. The authorities additional mentioned that 67.6% of India’s inhabitants above 6 years have been discovered to have SARS-CoV-2 antibodies and that 85 per cent of surveyed healthcare employees had antibodies in opposition to SARS-CoV-2 whereas one-tenth of HCWs nonetheless unvaccinated.
Meanwhile, 4 Covid-19 vaccine candidates are at completely different phases of human trials whereas one, developed by Genique Life Sciences, is within the superior pre-clinical stage, Union Science and Technology Minister Jitendra Singh mentioned on Tuesday in a written response to a query within the Rajya Sabha, information company PTI reported.
He mentioned that Cadila Healthcare Ltd’s DNA-based vaccine candidate is in section three medical trial and it has additionally submitted the interim knowledge for emergency use authorisation. Biological E Ltd’s vaccine candidate can be in section three medical trial. Bharat Biotech International Ltd’s Adeno intranasal vaccine candidate is in section three medical trial, whereas Gennova Biopharmaceuticals Ltd’s mRNA-vaccine candidate is in Phase one medical trial. The Gurgaon-based Genique Life Sciences Pvt Ltd’s vaccine candidate is within the superior pre-clinical stage, he added.